<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520806</url>
  </required_header>
  <id_info>
    <org_study_id>RLX.CHF.003</org_study_id>
    <nct_id>NCT00520806</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure</brief_title>
  <acronym>RELAX-AHF</acronym>
  <official_title>A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different doses of relaxin will be compared to placebo to determine efficacy and safety for
      the treatment of patients hospitalized with acute heart failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, randomized, double-blind, placebo-controlled, Phase II/III trial of
      intravenous recombinant relaxin for the treatment of signs and symptoms in patients
      hospitalized for acute decompensated heart failure. The Phase II pilot study has completed;
      the Phase III main portion of the trial is ongoing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of dyspnea in acute heart failure</measure>
    <time_frame>Up to day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV death or rehospitalization due to heart failure or renal failure</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1161</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>48 hour iv infusion of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 hour iv infusion of relaxin at 30 ug/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relaxin</intervention_name>
    <description>Intravenous infusion for 48 h at 30 ug/kg/day</description>
    <arm_group_label>Relaxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion for 48 h</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized for acute heart failure

          -  Dyspnea at rest or with minimal exertion

          -  Pulmonary congestion

          -  Able to provide informed consent

          -  Systolic blood pressure &gt; 125 mmHg

          -  Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2

        Exclusion Criteria:

          -  Use of other IV therapies for acute heart failure

          -  Fever or sepsis

          -  Recent major neurologic event

          -  Recent major surgery

          -  Recent acute coronary syndrome

          -  Other recent investigational drug use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Severin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Institute</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2007</study_first_submitted>
  <study_first_submitted_qc>August 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Renal dysfunction</keyword>
  <keyword>Relaxin</keyword>
  <keyword>Vasodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methocarbamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

